Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Apr 27;6:31. doi: 10.1186/1756-8722-6-31

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013 Falcon et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Targeting the VEGF-independent cords. VEGF stimulated ADSC/ECFC co-cultures established for 4 days were treated with a concentration response of suramin (a) or combretastatin (b). The effects on the tube length of the established cords were continuously monitored from the day of drug addition. (c) Continuous monitoring of the effect of ramucirumab (Ram), a gamma secretase inhibitor (GSI; LY411575), or the Ram/GSI combination on the tube length of 4 day established cords. (d) Images of blood vessels stained with CD31 within the implants after treatment with IgG, ramucirumab (Ram), a gamma secretase inhibitor (GSI; LY411575), or the combination of Ram and the GSI beginning after 4 days of establishment (left). Graph of the percent area of CD31 after 4 days of treatment beginning on day 4 (right). n = 10 per treatment group. * = p < 0.01 vs. hIgG control. † = p < 0.001 vs. all other groups.